RT Journal Article
SR Electronic
T1 Childhood maltreatment and subsequent risk of hospitalization or death due to COVID-19: a cohort study in the UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.12.23295354
DO 10.1101/2023.09.12.23295354
A1 Wang, Yue
A1 Ge, Fenfen
A1 Aspelund, Thor
A1 Ask, Helga
A1 Hauksdóttir, Arna
A1 Hu, Kejia
A1 Jakobsdóttir, Jóhanna
A1 Zoega, Helga
A1 Shen, Qing
A1 Whalley, Heather C
A1 Vesterager Pedersen, Ole Birger
A1 Lehto, Kelli
A1 Andreassen, Ole A
A1 Fang, Fang
A1 Song, Huan
A1 Valdimarsdóttir, Unnur A
YR 2023
UL http://medrxiv.org/content/early/2023/09/12/2023.09.12.23295354.abstract
AB Childhood maltreatment has been associated with some infection-related outcomes, yet its potential role in severe COVID-19 outcomes has not been addressed. Therefore, leveraging longitudinal data from the population-based UK Biobank (N=151,427), our study aimed to explore the association between childhood maltreatment and severe COVID-19 outcomes (i.e., hospitalization or death due to COVID-19) and its underlying mechanisms. Our results suggest that childhood maltreatment, particularly physical neglect, is associated with a 54.0% increased risk of severe COVID-19 outcomes (i.e., hospitalization or death due to COVID-19), which was not modified by genetic predisposition to severe COVID-19 outcomes. We found that 50.9% of this association was mediated by suboptimal socioeconomic status, lifestyle and prepandemic somatic diseases or psychiatric disorders. These findings highlight the role of early life adversities in severe health consequences across the lifespan and call for increased clinical surveillance of people exposed to childhood maltreatment in COVID-19 outbreaks and future pandemics.Competing Interest StatementOAA is a consultant to cortechs.ai, and received speaker's honorarium from Lundbeck, Sunovion and Janssen. All other authors declare that they have no competing interests.Funding StatementThis work was supported by NordForsk (NO. 105668/138929 to UAV) and a Horizon2020 grant (will provident). YW was supported by the China Scholarship Council (NO. 202106240012). HA was supported by the Research Council of Norway (RCN, #324620) and NordForsk (NO. 156298). OAA was supported by RCN (#223273, #324499). HZ was supported by an UNSW Scientia Program Award. KL was supported by the Estonian Research Council (NO. PSG615).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data from the UK Biobank (http://www.ukbiobank.ac.uk/) are available to all researchers upon making an application.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from the UK Biobank (http://www.ukbiobank.ac.uk/) are available to all researchers upon making an application.